



Editorial

An Urgent Need to Focus on Youth With Opioid Use Disorder



Youth deaths are driven by the same patterns of theAs COVID-19 tore through communities, preliminary data suggest that overdose deaths climbed to greater than 100,000 during the 12-month period ending in September 2021 [1]. Approximately 75% of those deaths were opioid-related, and most were fentanyl-involved [2]. This overdose crisis has not spared youth. Prior to the emergence of COVID-19, synthetic opioid-related overdose deaths increased 2925% between 1999 and 2016 among young people [3]. Between 2019 and 2020, overdose death rates increased 49% among 15- to 24-year-olds. Starting in 2020, adolescents experienced a greater relative increase in overdoses than adults [4]. Furthermore, the pandemic has highlighted widening racial and ethnic disparities in overdose deaths among youth. American Indian or Alaskan Indian youth have the highest overdose death rate, and Latinx youth have the second highest. Between 2019 and 2020, the overdose death rate doubled among Black youth [4].

Youth deaths are driven by the same patterns of the opioid type seen in older adults: in the early 2000s mainly prescription opioids with a transition to heroin around 2012 and then to fentanyl in recent years [5]. Even the increase seen in stimulant-involved deaths mirrors the rising impact of these substances in adult populations. In 2017, fatal overdoses that included an opioid plus another substance surpassed the opioid-only deaths [6]. During that time, we have continued to see high rates of unmet need for interventions that reduce opioid-related morbidity and mortality. Medications (such as buprenorphine) are recommended treatment for youth with opioid use disorder. Buprenorphine improves retention in care, reduces opioid use, and decreases behaviors associated with HIV [7]. From adult studies, we can extrapolate that these medications are life-saving [8]. Despite this, use of buprenorphine prior to the emergence of COVID-19 use was decreasing among youth [9]. Prior work found that among Medicaid-enrolled and commercially insured youth with a diagnosis of opioid use disorder, less than 25% received timely medication treatment. Black youth were even less likely to receive medication than their White peers [10].

The COVID-19 pandemic led to federal regulations related to substance use disorder treatment that allowed for providers to

initiate buprenorphine over telehealth and loosened regulations related to methadone dosing. In this context, studies focused on understanding the impact of COVID-19 on treatment access, particularly among youth who are critical [11]. In this issue of Journal of Adolescent Health, finding by Alinsky et al. [12] that during the early COVID-19 pandemic, buprenorphine prescription paid with commercial insurance or cash among young adults significantly decreased is especially striking. In their study, the authors examined patient-level buprenorphine prescription data between January 2018 and August 2020 to understand the potential impact of COVID-19. They stratified their analyses by three age groups: 12–17, 18–24, and 25–29 years.

Youth deaths are driven by the same patterns of theAlinsky et al. found that although overall monthly prescriptions of buprenorphine decreased among those aged 18–29 years, this was driven by decreases in commercial prescriptions and cash prescriptions. A similar decrease was not seen among those filling medications with Medicaid. The significant decrease in buprenorphine prescriptions among young adults aged 18–29 years of age suggests worse access to life-saving opioid treatments during a time when opioid-related mortality was skyrocketing. As the pandemic evolved, layoffs and financial stressors may have contributed to reduced ability for patients to pay cash. Individuals who had commercial insurance may have lost it, and there was not a concurrent rise in Medicaid fills by this group. It is therefore possible that these young people may have fallen out of care. The persistent access to safety net insurance programs, like Medicaid, allows its recipients to have more consistent and stable access to addiction treatment. With the ongoing financial and social stressors experienced during the early years of the pandemic, this access is more critical than ever. This work highlights the importance of exploring policy changes that expand Medicaid eligibility, particularly among youth.

Youth deaths are driven by the same patterns of theInterestingly, among 12- to 17-year-olds, the monthly rate of buprenorphine prescriptions covered by Medicaid or commercial insurance increased during the pandemic. It might be that more youths were identified with opioid use disorder and/or offered treatment with medication during this time. It

See Related Articles on p.239

Conflicts of interest: The authors have no conflicts of interest to declare.

could also reflect that more young people found it easier to access medication because of the flexible regulations around prescribing during the pandemic. As cash fills in this age group declined while insurance fills increased, it might also reflect greater willingness for the youngest cohort to use their family health insurance and to engage or involve their families in their addiction treatment.

The syndemics of COVID-19 and the overdose crisis have had a profound impact on the lives of individuals across the United States, including youth and those from minoritized and marginalized communities. A recent study found 1.25 million years of life lost among young people aged 10–24 years to unintentional drug overdose between 2015 and 2019 [13]. The most potent intervention to flatten and reverse this trend is medications for opioid use disorder. We urgently need additional research to examine the factors influencing youth access and adoption of medications to treat opioid use disorder, focused educational initiatives to increase prescribing at the time of diagnosis, and increased advocacy to support structural and policy changes at the federal and state level to increase equitable and persistent access to life-saving treatment.

Funding Sources

Dr. Bagley is supported by K23DA044324. Dr. Wilson is supported by NIDA K23DA048987.

J. Deanna Wilson, M.D.

Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Sarah M. Bagley, M.D., M.Sc.

Department of Medicine, Boston University School of Medicine, Boston, Massachusetts

Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts

Grayken Center for Addiction, Boston Medical Center, Boston, Massachusetts

References

- [1] Centers for Disease Control and Prevention. COVID data tracker. Atlanta, GA: US Department of Health and Human Services. Available at: <https://covid.cdc.gov/covid-data-tracker>. Accessed April 8, 2022.
- [2] Ahmad F, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2021. Available at: <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>. Accessed April 9, 2021.
- [3] Gaither JR, Shabanova V, Leventhal JM. US national trends in pediatric deaths from prescription and illicit opioids, 1999–2016. *JAMA Netw Open* 2018;1:e186558.
- [4] Friedman J, Godvin M, Shover CL, et al. Trends in drug overdose deaths among US adolescents, January 2010 to June 2021. *JAMA* 2022;327:1398.
- [5] Centers for Disease Control and Prevention; National Center for Health Statistics. Multiple cause of death 1999–2017 on CDC WONDER Online Database. Atlanta: Centers for Disease Control and Prevention, Wide-ranging Online Data for Epidemiologic Research Online Database; 2018.
- [6] Lim JK, Earlywine JJ, Bagley SM, et al. Polysubstance involvement in opioid overdose deaths in adolescents and young adults, 1999–2018. *JAMA Pediatr* 2021;175:194.
- [7] Robinson CA, Wilson JD. Management of opioid misuse and opioid use disorders among youth. *Pediatrics* 2020;145:S153–64.
- [8] Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. *Ann Intern Med* 2018;169:137.
- [9] Olfson M, Zhang VS, Schoenbaum M, King M. Trends in buprenorphine treatment in the United States, 2009–2018. *JAMA* 2020;323:276.
- [10] Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001–2014. *JAMA Pediatr* 2017;171:747.
- [11] Gramlich J. Recent surge in U.S. drug overdose deaths has hit Black men the hardest. Pew Research Center. 2022. Available at: <https://www.pewresearch.org/fact-tank/2022/01/19/recent-surge-in-u-s-drug-overdose-deaths-has-hit-black-men-the-hardest/>. Accessed June 3, 2022.
- [12] Alinsky RH, Prichett L, Hsien-Chang Y, Alexander GC, Stein BD, Saloner B. Treatment of opioid use disorder with buprenorphine among US adolescents & young adults during the early COVID-19 pandemic. *J Adolesc Health* 2022;71:231–41.
- [13] Hall OT, Trimble C, Garcia S, Entrup P, Deaner M, Teater J. Unintentional drug overdose mortality in years of life lost among adolescents and young people in the US from 2015 to 2019. *JAMA Pediatr* 2022;176:415.